JN Biosciences LLC

Bridging Science to Life

JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043

  • Home
  • ManagementClick to open the Management menu
    • Naoya Tsurushita, Ph.D.
    • J Yun Tso, Ph.D.
  • Technology
  • PipelineClick to open the Pipeline menu
    • CD122
    • Death Receptors
    • Costimulatory Molecules
    • Checkpoint Molecules
    • Bispecific antibodies
  • Humanization
  • Partnering
  • NewsClick to open the News menu
    • 2022
    • 2021
    • 2019 - 2020
    • 2018
    • 2017
    • 2016
    • 2012 - 2015
  • Contact

2019 - 2020

May 28, 2020

A phase 2 clinical study with a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) sponsored by Arcus Biosciences for treatment of non-small cell lung cancer was initiated (NCT04262856).  The title of the study is "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)."

January 21, 2020

A U.S. Patent entitled "Antibodies to TIGIT" (US10537633), on which JN Biosciences' J Yun Tso and Naoya Tsurushita are inventors, was issued.  

Copyright 2022 JN Biosciences. All rights reserved.

 

JN Biosciences LLC
320 Logue Avenue
Mountain View, CA 94043